The immunoregulator soluble TACI Is released by ADAM10 and reflects B cell activation in autoimmunity

Franziska S. Hoffmann, Peer Hendrik Kuhn, Sarah A. Laurent, Stefanie M. Hauck, Kerstin Berer, Simone A. Wendlinger, Markus Krumbholz, Mohsen Khademi, Tomas Olsson, Martin Dreyling, Hans Walter Pfister, Tobias Alexander, Falk Hiepe, Tania Kümpfel, Howard C. Crawford, Hartmut Wekerle, Reinhard Hohlfeld, Stefan F. Lichtenthaler, Edgar Meinl

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

BAFF and a proliferation-inducing ligand (APRIL), which control B cell homeostasis, are therapeutic targets in autoimmune diseases. TACI-Fc (atacicept), a soluble fusion protein containing the extracellular domain of the BAFF-APRIL receptor TACI, was applied in clinical trials. However, disease activity in multiple sclerosis unexpectedly increased, whereas in systemic lupus erythematosus, atacicept was beneficial. In this study, we show that an endogenous soluble TACI (sTACI) exists in vivo. TACI proteolysis involved shedding by a disintegrin and metalloproteinase 10 releasing sTACI from activated B cells. The membrane-bound stub was subsequently cleaved by g-secretase reducing ligand-independent signaling of the remaining C-terminal fragment. The shed ectodomain assembled ligand independently in a homotypic way. It functioned as a decoy receptor inhibiting BAFF- And APRIL-mediated B cell survival and NF-kB activation. We determined sTACI levels in autoimmune diseases with established hyperactivation of the BAFF-APRIL system. sTACI levels were elevated both in the cerebrospinal fluid of the brain-restricted autoimmune disease multiple sclerosis correlating with intrathecal IgG production, as well as in the serum of the systemic autoimmune disease systemic lupus erythematosus correlating with disease activity. Together, we show that TACI is sequentially processed by a disintegrin and metalloproteinase 10 and g-secretase. The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation.

Original languageEnglish (US)
Pages (from-to)542-552
Number of pages11
JournalJournal of Immunology
Volume194
Issue number2
DOIs
StatePublished - Jan 15 2015

Fingerprint

Autoimmunity
B-Lymphocytes
Ligands
Autoimmune Diseases
Disintegrins
Amyloid Precursor Protein Secretases
Metalloproteases
Systemic Lupus Erythematosus
Transmembrane Activator and CAML Interactor Protein
Multiple Sclerosis
B-Cell Activation Factor Receptor
NF-kappa B
Proteolysis
Cerebrospinal Fluid
Cell Survival
Homeostasis
Immunoglobulin G
Clinical Trials
Membranes
Brain

ASJC Scopus subject areas

  • Immunology

Cite this

Hoffmann, F. S., Kuhn, P. H., Laurent, S. A., Hauck, S. M., Berer, K., Wendlinger, S. A., ... Meinl, E. (2015). The immunoregulator soluble TACI Is released by ADAM10 and reflects B cell activation in autoimmunity. Journal of Immunology, 194(2), 542-552. https://doi.org/10.4049/jimmunol.1402070

The immunoregulator soluble TACI Is released by ADAM10 and reflects B cell activation in autoimmunity. / Hoffmann, Franziska S.; Kuhn, Peer Hendrik; Laurent, Sarah A.; Hauck, Stefanie M.; Berer, Kerstin; Wendlinger, Simone A.; Krumbholz, Markus; Khademi, Mohsen; Olsson, Tomas; Dreyling, Martin; Pfister, Hans Walter; Alexander, Tobias; Hiepe, Falk; Kümpfel, Tania; Crawford, Howard C.; Wekerle, Hartmut; Hohlfeld, Reinhard; Lichtenthaler, Stefan F.; Meinl, Edgar.

In: Journal of Immunology, Vol. 194, No. 2, 15.01.2015, p. 542-552.

Research output: Contribution to journalArticle

Hoffmann, FS, Kuhn, PH, Laurent, SA, Hauck, SM, Berer, K, Wendlinger, SA, Krumbholz, M, Khademi, M, Olsson, T, Dreyling, M, Pfister, HW, Alexander, T, Hiepe, F, Kümpfel, T, Crawford, HC, Wekerle, H, Hohlfeld, R, Lichtenthaler, SF & Meinl, E 2015, 'The immunoregulator soluble TACI Is released by ADAM10 and reflects B cell activation in autoimmunity', Journal of Immunology, vol. 194, no. 2, pp. 542-552. https://doi.org/10.4049/jimmunol.1402070
Hoffmann, Franziska S. ; Kuhn, Peer Hendrik ; Laurent, Sarah A. ; Hauck, Stefanie M. ; Berer, Kerstin ; Wendlinger, Simone A. ; Krumbholz, Markus ; Khademi, Mohsen ; Olsson, Tomas ; Dreyling, Martin ; Pfister, Hans Walter ; Alexander, Tobias ; Hiepe, Falk ; Kümpfel, Tania ; Crawford, Howard C. ; Wekerle, Hartmut ; Hohlfeld, Reinhard ; Lichtenthaler, Stefan F. ; Meinl, Edgar. / The immunoregulator soluble TACI Is released by ADAM10 and reflects B cell activation in autoimmunity. In: Journal of Immunology. 2015 ; Vol. 194, No. 2. pp. 542-552.
@article{3718b5290b864a83a217214ce5fdd025,
title = "The immunoregulator soluble TACI Is released by ADAM10 and reflects B cell activation in autoimmunity",
abstract = "BAFF and a proliferation-inducing ligand (APRIL), which control B cell homeostasis, are therapeutic targets in autoimmune diseases. TACI-Fc (atacicept), a soluble fusion protein containing the extracellular domain of the BAFF-APRIL receptor TACI, was applied in clinical trials. However, disease activity in multiple sclerosis unexpectedly increased, whereas in systemic lupus erythematosus, atacicept was beneficial. In this study, we show that an endogenous soluble TACI (sTACI) exists in vivo. TACI proteolysis involved shedding by a disintegrin and metalloproteinase 10 releasing sTACI from activated B cells. The membrane-bound stub was subsequently cleaved by g-secretase reducing ligand-independent signaling of the remaining C-terminal fragment. The shed ectodomain assembled ligand independently in a homotypic way. It functioned as a decoy receptor inhibiting BAFF- And APRIL-mediated B cell survival and NF-kB activation. We determined sTACI levels in autoimmune diseases with established hyperactivation of the BAFF-APRIL system. sTACI levels were elevated both in the cerebrospinal fluid of the brain-restricted autoimmune disease multiple sclerosis correlating with intrathecal IgG production, as well as in the serum of the systemic autoimmune disease systemic lupus erythematosus correlating with disease activity. Together, we show that TACI is sequentially processed by a disintegrin and metalloproteinase 10 and g-secretase. The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation.",
author = "Hoffmann, {Franziska S.} and Kuhn, {Peer Hendrik} and Laurent, {Sarah A.} and Hauck, {Stefanie M.} and Kerstin Berer and Wendlinger, {Simone A.} and Markus Krumbholz and Mohsen Khademi and Tomas Olsson and Martin Dreyling and Pfister, {Hans Walter} and Tobias Alexander and Falk Hiepe and Tania K{\"u}mpfel and Crawford, {Howard C.} and Hartmut Wekerle and Reinhard Hohlfeld and Lichtenthaler, {Stefan F.} and Edgar Meinl",
year = "2015",
month = "1",
day = "15",
doi = "10.4049/jimmunol.1402070",
language = "English (US)",
volume = "194",
pages = "542--552",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - The immunoregulator soluble TACI Is released by ADAM10 and reflects B cell activation in autoimmunity

AU - Hoffmann, Franziska S.

AU - Kuhn, Peer Hendrik

AU - Laurent, Sarah A.

AU - Hauck, Stefanie M.

AU - Berer, Kerstin

AU - Wendlinger, Simone A.

AU - Krumbholz, Markus

AU - Khademi, Mohsen

AU - Olsson, Tomas

AU - Dreyling, Martin

AU - Pfister, Hans Walter

AU - Alexander, Tobias

AU - Hiepe, Falk

AU - Kümpfel, Tania

AU - Crawford, Howard C.

AU - Wekerle, Hartmut

AU - Hohlfeld, Reinhard

AU - Lichtenthaler, Stefan F.

AU - Meinl, Edgar

PY - 2015/1/15

Y1 - 2015/1/15

N2 - BAFF and a proliferation-inducing ligand (APRIL), which control B cell homeostasis, are therapeutic targets in autoimmune diseases. TACI-Fc (atacicept), a soluble fusion protein containing the extracellular domain of the BAFF-APRIL receptor TACI, was applied in clinical trials. However, disease activity in multiple sclerosis unexpectedly increased, whereas in systemic lupus erythematosus, atacicept was beneficial. In this study, we show that an endogenous soluble TACI (sTACI) exists in vivo. TACI proteolysis involved shedding by a disintegrin and metalloproteinase 10 releasing sTACI from activated B cells. The membrane-bound stub was subsequently cleaved by g-secretase reducing ligand-independent signaling of the remaining C-terminal fragment. The shed ectodomain assembled ligand independently in a homotypic way. It functioned as a decoy receptor inhibiting BAFF- And APRIL-mediated B cell survival and NF-kB activation. We determined sTACI levels in autoimmune diseases with established hyperactivation of the BAFF-APRIL system. sTACI levels were elevated both in the cerebrospinal fluid of the brain-restricted autoimmune disease multiple sclerosis correlating with intrathecal IgG production, as well as in the serum of the systemic autoimmune disease systemic lupus erythematosus correlating with disease activity. Together, we show that TACI is sequentially processed by a disintegrin and metalloproteinase 10 and g-secretase. The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation.

AB - BAFF and a proliferation-inducing ligand (APRIL), which control B cell homeostasis, are therapeutic targets in autoimmune diseases. TACI-Fc (atacicept), a soluble fusion protein containing the extracellular domain of the BAFF-APRIL receptor TACI, was applied in clinical trials. However, disease activity in multiple sclerosis unexpectedly increased, whereas in systemic lupus erythematosus, atacicept was beneficial. In this study, we show that an endogenous soluble TACI (sTACI) exists in vivo. TACI proteolysis involved shedding by a disintegrin and metalloproteinase 10 releasing sTACI from activated B cells. The membrane-bound stub was subsequently cleaved by g-secretase reducing ligand-independent signaling of the remaining C-terminal fragment. The shed ectodomain assembled ligand independently in a homotypic way. It functioned as a decoy receptor inhibiting BAFF- And APRIL-mediated B cell survival and NF-kB activation. We determined sTACI levels in autoimmune diseases with established hyperactivation of the BAFF-APRIL system. sTACI levels were elevated both in the cerebrospinal fluid of the brain-restricted autoimmune disease multiple sclerosis correlating with intrathecal IgG production, as well as in the serum of the systemic autoimmune disease systemic lupus erythematosus correlating with disease activity. Together, we show that TACI is sequentially processed by a disintegrin and metalloproteinase 10 and g-secretase. The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation.

UR - http://www.scopus.com/inward/record.url?scp=84920487786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920487786&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1402070

DO - 10.4049/jimmunol.1402070

M3 - Article

C2 - 25505277

AN - SCOPUS:84920487786

VL - 194

SP - 542

EP - 552

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -